Entrada Therapeutics

Headquartered in Boston’s Seaport community, Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. Our Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of active moieties into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, we are advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. Our lead oligonucleotide programs are in development for the treatment of people living with Duchenne muscular dystrophy who are exon 44, 45 and 50 skipping amenable. Entrada has partnered VX-670, a clinical-stage program for the treatment of myotonic dystrophy type 1. For more information about Entrada, please visit our website, www.entradatx.com